The fund seeks capital appreciation in the long term by investing in large-and mid-size companies in the United States.
The investment process is designed to highlight companies in the benchmark index that are engaged in the health sciences companies.
The process focuses on companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.
Then the research team relies on fundamental analysis to identify high-quality companies that represent the most compelling investment opportunities.
The team considers companies with rapid earnings growth relative to inflation and the economy. In addition, the team seeks companies that are estimated to trade below their fair values.
The fund may seek investments in companies that are developing new and effective medicines, as well as companies whose business models reduce costs or improve quality in health care systems.
Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.
The manager divides the health sciences sector into four main areas namely pharmaceutical companies; health care services companies; medical products and devices providers; and biotechnology firms.
Next, the manager allocates capital depending on the relative potential within each area and the outlook for the overall health sciences sector.
The fund may purchase a security if it believes there could be an increase in value as a result of an extraordinary corporate event, a new product introduction or innovation, a favorable competitive development, or a management change.
The fund has the flexibility to invest across all market capitalizations.
The fund is non-diversified and may invest a greater percentage of its net assets in fewer issuers than a diversified fund.